New transparency regulations are now in place that may effect your global pharmaceutical organization.
Allow d-wise experts to provide effective, streamlined anonymization services at scale and cost. With one partnership, identify and classify the study variables, measure the re-identification risk and anonymize the data and study reports for submission to regulatory agencies.
Through one partnership obtain leading technology and domain experts to automate transparency for your organization.
To meet the emerging anonymization needs of the industry, d-wise developed Blur, an application-based de-identification solution. Blur provides an enhanced platform for de-identification, a critical tool for any life sciences firm submitting data to regulatory agencies or sharing clinical trial findings externally or internally. Specific benefits include: